- Home
- CUB vs AKBA Comparison
CUB vs AKBA Comparison
Compare CUB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- AKBA
- Stock Information
- Founded
- CUB 2024
- AKBA 2007
- Country
- CUB United States
- AKBA United States
- Employees
- CUB N/A
- AKBA N/A
- Industry
- CUB
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- AKBA Health Care
- Exchange
- CUB NYSE
- AKBA Nasdaq
- Market Cap
- CUB 310.7M
- AKBA 336.2M
- IPO Year
- CUB 2024
- AKBA 2014
- Fundamental
- Price
- CUB $10.24
- AKBA $1.91
- Analyst Decision
- CUB
- AKBA Strong Buy
- Analyst Count
- CUB 0
- AKBA 3
- Target Price
- CUB N/A
- AKBA $6.50
- AVG Volume (30 Days)
- CUB 20.6K
- AKBA 6.0M
- Earning Date
- CUB 01-01-0001
- AKBA 05-08-2025
- Dividend Yield
- CUB N/A
- AKBA N/A
- EPS Growth
- CUB N/A
- AKBA N/A
- EPS
- CUB N/A
- AKBA N/A
- Revenue
- CUB N/A
- AKBA $160,180,000.00
- Revenue This Year
- CUB N/A
- AKBA $23.40
- Revenue Next Year
- CUB N/A
- AKBA $58.44
- P/E Ratio
- CUB $44.90
- AKBA N/A
- Revenue Growth
- CUB N/A
- AKBA N/A
- 52 Week Low
- CUB $9.96
- AKBA $0.80
- 52 Week High
- CUB $10.55
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- AKBA 45.97
- Support Level
- CUB N/A
- AKBA $1.83
- Resistance Level
- CUB N/A
- AKBA $2.22
- Average True Range (ATR)
- CUB 0.00
- AKBA 0.21
- MACD
- CUB 0.00
- AKBA -0.03
- Stochastic Oscillator
- CUB 0.00
- AKBA 28.21
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.